As the pharmaceutical industry accelerates its digital and cloud-native transformation, enterprise middle-platform and microservice architectures are growing increasingly complex, and traditional, fragmented operations tools can no longer meet the needs of modern IT operations. Bonree Data has partnered with Nanjing Pharmaceutical Co., Ltd. (“Nanjing Pharmaceutical”), applying the Bonree ONE unified intelligent observability platform to close the observability gaps in its cloud-native architecture. The company has fully upgraded its operations model from manual, reactive troubleshooting to AI-driven proactive diagnosis, laying a solid foundation for the stable operation of its core business systems and supporting the long-term, steady development of its digital supply chain and internet-based pharmaceutical business.

Project Background

As an industry-leading pharmaceutical enterprise, Nanjing Pharmaceutical is actively advancing the digital upgrade of its business, and its core systems are built on advanced cloud-native and middle-platform architectures. However, as business complexity continues to rise, the traditional operations model faces serious challenges:

Difficulty pinpointing the root cause of faults. The enterprise’s core business middle platform depends heavily on underlying databases, middleware, and other infrastructure software. When a business anomaly occurs, it is impossible to quickly and accurately determine which component or call link the fault lies in. The troubleshooting direction is unclear and requires repeated trial and error.

Lack of an observability perspective. Existing monitoring tools (such as Zabbix) focus on hardware metrics at the infrastructure level and lack in-depth insight into the performance of key applications. As a result, faults are detected late, and the response is often reactive, triggered only after users complain.

Data silos. The metrics, logs, and trace data of each business system are fragmented and stored and managed independently. Troubleshooting requires manual correlation across systems, which is time-consuming and laborious, with a high rate of misjudgment, seriously affecting the efficiency of fault handling.

To address these pain points, Nanjing Pharmaceutical set clear goals for the intelligent governance of its operations:

Full-stack, end-to-end observability. Build an integrated observability platform that provides real-time monitoring and full-chain tracing of core business systems, microservices, and cloud-native infrastructure, eliminating monitoring blind spots.

Minute-level root cause localization. Use an AI-driven analysis engine to raise the accuracy of fault root cause localization to over 90%, greatly shortening mean time to recovery (MTTR) and strengthening business continuity assurance.

Data-driven decision-making. Through a standardized operations data model, consolidate scattered operations data into a reusable knowledge base, providing a scientific basis for system architecture optimization and capacity planning and supporting continuous improvement.

Application Scenarios

Built on the Bonree ONE platform, Nanjing Pharmaceutical deployed lightweight “intelligent probes” that, without changing existing application configurations, provide a comprehensive observability perspective across its complex IT environment:

Five-layer full-stack topology mapping and full-chain call tracing. The platform automatically discovers dependencies between applications and dynamically generates a global topology map with five layers: application, business system, service, process/Pod, and host. Administrators can intuitively see how an anomaly propagates across layers and the scope of its impact, and quickly determine the boundary of a fault.

Intelligent diagnosis and root cause analysis. When an anomaly occurs, the platform uses a causal inference engine to automatically correlate application performance, infrastructure metrics, and log data, and directly pinpoints specific code defects, configuration errors, or slow database queries, greatly reducing manual troubleshooting effort.

Panoramic service health monitoring and proactive alerting. The Bonree ONE platform performs continuous, 24/7 health inspections of 172 monitored services and 326 instances, covering both production and pre-production environments. Through a three-tier structure of system, service, and instance, it supports step-by-step drill-down as well as topology analysis of horizontal dependencies and vertical stacks. Alerts are graded by severity and can be pushed via DingTalk and email. Combined with an alert convergence mechanism, this effectively reduces false alarms and ultimately enables problems to be detected, flagged, and handled early.

End-user experience observability. Nanjing Pharmaceutical delivers rich content and services to users through multiple channels, including websites, apps, mini programs, and H5 pages. Comprehensive monitoring coverage is key to ensuring stable application operation in the pharmaceutical industry. By monitoring key data such as application performance metrics and application runtime status in real time, and by providing visual monitoring tools, Bonree Data has delivered full-stack monitoring for Nanjing Pharmaceutical. This gives the company a complete picture of the running status of its applications and services, with end-to-end monitoring from user behavior down to the code level.

Coverage across all business domains. Bonree ONE’s intelligent observability capabilities now deeply cover 24 core business systems at Nanjing Pharmaceutical. These span key business areas including WMS (warehouse management system), ERP (enterprise resource planning system), master data management, BMS (settlement management system), the logistics visualization platform, supply chain finance, the retail middle platform, the prescription circulation platform, the member center, and various mobile-side APIs, achieving comprehensive observability from back-end support to front-end business.

Project Results and Benefits: Availability Target for Core Business Systems Raised to 99.99%

With the Bonree ONE platform, Nanjing Pharmaceutical has made the leap from technical support to business enablement:

Ensuring business continuity. The availability target for core business systems has been raised to 99.99%, effectively supporting strategic initiatives such as smart healthcare and “Internet Plus Pharmaceuticals,” and providing a solid technical foundation for rapid business growth.

Significant cost reduction and efficiency gains. Through intelligent alert noise reduction and automatic root cause localization, the time previously spent on data collection and preliminary analysis, which accounted for about 70% of the operations process, has been greatly reduced. Mean time to repair is expected to be shortened by 90%, allowing the operations team to devote more effort to architecture optimization and business innovation.

Optimized resource governance. Through real-time monitoring and trend analysis of resource utilization, uneven server allocation and resource waste can be precisely identified. This provides data support for dynamic resource scheduling and capacity planning and effectively reduces infrastructure costs.

About Nanjing Pharmaceutical

Nanjing Pharmaceutical Co., Ltd. was founded in 1951 and listed on the Shanghai Stock Exchange in 1996. It is one of the earlier listed companies in China’s pharmaceutical distribution industry and has grown into a cross-regional, network-based group enterprise. Rooted in the health industry, the company’s main businesses are pharmaceutical wholesale and pharmaceutical retail, and it is a leading regional pharmaceutical commercial enterprise in China’s pharmaceutical distribution industry.